Stock Quotes & Company News | Reuters.com
Edition:
United States

People: Bayer AG (BAYGn.DE)

BAYGn.DE on Xetra

89.96EUR
7:03am EDT
Change (% chg)

€0.82 (+0.92%)
Prev Close
€89.14
Open
€90.49
Day's High
€90.95
Day's Low
€89.55
Volume
1,038,552
Avg. Vol
3,095,978
52-wk High
€138.00
52-wk Low
€83.45

Malik, Kemal 

Dr. Kemal Malik is Member of the Management Board, Innovation and the Latin America Region at the company. He studied medicine at Charing Cross and Westminster Medical School (University of London), graduating as a Bachelor of Medicine, Bachelor of Surgery (MBBS) in 1987. Malik subsequently spent several years in clinical medicine at the Northwick Park Clinical Research Centre and at Hammersmith Hospital, London. He then held various positions of increasing responsibility in medical affairs and clinical development at Bristol-Myers Squibb in the United Kingdom. Malik joined Bayer in 1995 as Head of Metabolism and Oncology Europe in the then Pharmaceuticals Business Group. He subsequently served as Head of Global Medical Development before being appointed Head of Global Development. Kemal Malik was a member of the Executive Committee of Bayer HealthCare AG from July 1, 2007 until his appointment to the Board of Management of Bayer AG. He was also Head of Global Development and Chief Medical Officer in the Pharmaceuticals Division.

Basic Compensation

Total Annual Compensation, EUR 659,000
Restricted Stock Awards, EUR --
Long-Term Incentive Plans, EUR --
All Other, EUR 72,000
Fiscal Year Total, EUR 731,000

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --